Jim Cramer on SELLAS: “It’s a Great Spec”
Key takeaways
- Jim Cramer on SELLAS: “It’s a Great Spec” Syeda Seirut Javed Tue, June 2, 2026 at 12:33 AM GMT+7 1 min read SLS SELLAS Life Sciences Group, Inc.
- Oh, this life science company that is, look, okay, so this is a good example.
- (NASDAQ:SLS) is a clinical-stage company focused on creating new treatments for cancer, specifically targeting the disease with its main product candidates, galinpepimut-S and SLS009.
Jim Cramer on SELLAS: “It’s a Great Spec” Syeda Seirut Javed Tue, June 2, 2026 at 12:33 AM GMT+7 1 min read SLS SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) was one of the stocks on Jim Cramer’s radar on Mad Money as he explained that many investors might be missing out on the market’s biggest winners. Responding to a caller’s question about the company, Cramer stated:
Oh, this life science company that is, look, okay, so this is a good example. This stock’s up a great deal, alright? And you know, it’s losing a little money. It’s a great spec, and even though it’s up, I used to say, you know, I can’t touch it. I used to say that. I can’t do that right now, I can’t. I’m going to say two thumbs up or whatever to SLS. It. It’s that kind of market.
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) is a clinical-stage company focused on creating new treatments for cancer, specifically targeting the disease with its main product candidates, galinpepimut-S and SLS009. To advance these treatments forward, the company partners with major names like Merck, GenFleet Therapeutics, and Memorial Sloan Kettering Cancer Center for clinical trials and development.